Log In
Print
BCIQ
Print
Print this Print this
 

bioerodible latanprost implant (Durasert)

  Manage Alerts
Collapse Summary General Information
Company pSivida Corp.
DescriptionSustained-release, bioerodible implant delivering latanoprost into the subconjunctival space of the eye using pSivida's Durasert technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase I/II
Standard IndicationOcular hypertension
Indication DetailsReduce intraocular pressure in patients with ocular hypertension or glaucoma
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today